Seeking Alpha

DURECT -29% AH as FDA denies approval for Posidur

  • DURECT (DRRX) -29.2% AH as the FDA fails to approve the company's Posidur investigational drug for post-operative pain relief.
  • The FDA says the new drug application did not demonstrate that Posidur is safe, and additional clinical safety studies need to be conducted.
From other sites
Comments (1)
  • billy meeker
    , contributor
    Comments (5) | Send Message
     
    I have gone to college for 49 years studying subjects that interest me, from Human behavior, to math, I was wondering about the speed of light? how did they figure it out? Or the distance from the moon we are or sun; I noticed in the "method". & a sketch of a prism with a lot of ides beyond Newton in 200 BCE;
    13 Feb, 09:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector